Patient Name Mr. VIKAS KUMAR KABRA Lab No 4025009 UHID 40010835 **Collection Date** 24/02/2024 12:29PM 24/02/2024 1:06PM Age/Gender 36 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 24/02/2024 5:06PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 7976570610

BIOCHEMISTRY

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE (FASTING)
 86.0
 mg/dl
 71 - 109

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP) 67.0 mg/dl Non – Diabetic: - < 140 mg/dl Pre – Diabetic: - 140-199 mg/dl

Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

THYROID T3 T4 TSH Sample: Serum

| Т3 | 1.590 | ng/mL | 0.970 - 1.690 |
|-----|-------|--------|---------------|
| T4 | 8.39 | ug/dl | 5.53 - 11.00 |
| TSH | 1.93 | μIU/mL | 0.40 - 4.05 |

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

| Patient Name | Mr. VIKAS KUMAR KABRA | Lab No | 4025009 |
|---------------------------|-----------------------|-----------------|--------------------|
| UHID | 40010835 | Collection Date | 24/02/2024 12:29PM |
| Age/Gender IP/OP Location | 36 Yrs/Male | Receiving Date | 24/02/2024 1:06PM |
| | O-OPD | Report Date | 24/02/2024 5:06PM |
| Referred By | Dr. EHS CONSULTANT | Report Status | Final |
| Mobile No. | 7976570610 | | |

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

79

15

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

| LFT (LIVER FUNCTION TEST) | | | | Sample: Serum |
|---------------------------|------|-------|-------------|---------------|
| BILIRUBIN TOTAL | 0.58 | mg/dl | 0.00 - 1.20 | |
| BILIRUBIN INDIRECT | 0.38 | mg/dl | 0.20 - 1.00 | |
| BILIRUBIN DIRECT | 0.20 | mg/dl | 0.00 - 0.30 | |
| SGOT | 26.0 | U/L | 0.0 - 40.0 | |
| SGPT | 32.2 | U/L | 0.0 - 41.0 | |
| TOTAL PROTEIN | 7.2 | g/dl | 6.6 - 8.7 | |
| ALBUMIN | 4.4 | g/dl | 3.5 - 5.2 | |
| GLOBULIN | 2.8 | | 1.8 - 3.6 | |

U/L

Ratio

U/L

40 - 129

1.5 - 2.5

10.0 - 60.0

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

ALKALINE PHOSPHATASE

A/G RATIO

GGTP

Page: 2 Of 11

Patient Name Mr. VIKAS KUMAR KABRA Lab No 4025009 UHID **Collection Date** 24/02/2024 12:29PM 40010835 24/02/2024 1:06PM Age/Gender **Receiving Date** 36 Yrs/Male Report Date O-OPD **IP/OP Location** 24/02/2024 5:06PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 7976570610

BIOCHEMISTRY

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis. nutritional status

cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

| TOTAL CHOLESTEROL | 210 | | <200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High |
|-----------------------|-------|-------|--|
| HDL CHOLESTEROL | 37.5 | | High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female) |
| LDL CHOLESTEROL | 158.9 | | Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl |
| CHOLESTERO VLDL | 17 | mg/dl | 10 - 50 |
| TRIGLYCERIDES | 87 | | Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl |
| CHOLESTEROL/HDL RATIO | 6 | % | |

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name Mr. VIKAS KUMAR KABRA Lab No 4025009 UHID 40010835 **Collection Date** 24/02/2024 12:29PM

24/02/2024 1:06PM Age/Gender **Receiving Date** 36 Yrs/Male **Report Date IP/OP Location** O-OPD 24/02/2024 5:06PM

Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 7976570610

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are

synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

| UREA | 19.6 | mg/dl | 16.60 - 48.50 |
|------------|---------|--------|---------------|
| BUN | 9.0 | mg/dl | 6 - 20 |
| CREATININE | 0.75 | mg/dl | 0.70 - 1.20 |
| SODIUM | 134.0 L | mmol/L | 136 - 145 |
| POTASSIUM | 3.87 | mmol/L | 3.50 - 5.50 |
| CHLORIDE | 97.8 L | mmol/L | 98 - 107 |
| URIC ACID | 5.6 | mg/dl | 3.4 - 7.0 |
| CALCIUM | 8.74 | mg/dl | 8.60 - 10.00 |

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name Mr. VIKAS KUMAR KABRA Lab No 4025009 UHID 40010835 **Collection Date** 24/02/2024 12:29PM 24/02/2024 1:06PM Age/Gender **Receiving Date** 36 Yrs/Male Report Date O-OPD **IP/OP Location** 24/02/2024 5:06PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 7976570610

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.

POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM: - Method: ISE electrode. Interpretation: -Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Mr. VIKAS KUMAR KABRA **Patient Name** Lab No 4025009 UHID 40010835 **Collection Date** 24/02/2024 12:29PM 24/02/2024 1:06PM Age/Gender **Receiving Date** 36 Yrs/Male **Report Date IP/OP Location** O-OPD 24/02/2024 5:06PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 7976570610

BLOOD BANK INVESTIGATION

Biological Ref. Range Test Name Result Unit

BLOOD GROUPING "AB" Rh Positive

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name Lab No Mr. VIKAS KUMAR KABRA 4025009 **Collection Date** 24/02/2024 12:29PM UHID 40010835 24/02/2024 1:06PM Age/Gender **Receiving Date** 36 Yrs/Male **Report Date** O-OPD **IP/OP Location** 24/02/2024 5:06PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 7976570610

CLINICAL PATHOLOGY

| Test Name | Result | Unit | Biological Ref. Range | |
|-----------------------------|-------------|------|-----------------------|---------------|
| URINE SUGAR (POST PRANDIAL) | | | | Sample: Urine |
| URINE SUGAR (POST PRANDIAL) | NEGATIVE | | NEGATIVE | |
| | | | | |
| URINE SUGAR (RANDOM) | | | | Sample: Urine |
| URINE SUGAR (RANDOM) | NEGATIVE | | NEGATIVE | |
| | | | | |
| | | | | Sample: Urine |
| PHYSICAL EXAMINATION | | | | |
| VOLUME | 20 | ml | | |
| COLOUR | PALE YELLOW | | P YELLOW | |
| APPEARANCE | CLEAR | | CLEAR | |
| CHEMICAL EXAMINATION | | | | |
| PH | 6.5 | | 5.5 - 7.0 | |
| SPECIFIC GRAVITY | 1.010 | | 1.016-1.022 | |
| PROTEIN | NEGATIVE | | NEGATIVE | |
| SUGAR | NEGATIVE | | NEGATIVE | |
| BILIRUBIN | NEGATIVE | | NEGATIVE | |
| BLOOD | NEGATIVE | | | |
| KETONES | NEGATIVE | | NEGATIVE | |
| NITRITE | NEGATIVE | | NEGATIVE | |
| UROBILINOGEN | NEGATIVE | | NEGATIVE | |
| LEUCOCYTE | NEGATIVE | | NEGATIVE | |
| MICROSCOPIC EXAMINATION | | | | |
| WBCS/HPF | 1-2 | /hpf | 0 - 3 | |
| RBCS/HPF | 00 | /hpf | 0 - 2 | |
| EPITHELIAL CELLS/HPF | 1-2 | /hpf | 0 - 1 | |
| CASTS | NIL | | NIL | |
| CRYSTALS | NIL | | NIL | |

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Mr. VIKAS KUMAR KABRA **Patient Name** Lab No 4025009 UHID 40010835 **Collection Date** 24/02/2024 12:29PM 24/02/2024 1:06PM Age/Gender 36 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 24/02/2024 5:06PM **Referred By** Dr. EHS CONSULTANT Final

Report Status

7976570610 Mobile No.

CLINICAL PATHOLOGY

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name Mr. VIKAS KUMAR KABRA Lab No 4025009 UHID 40010835 **Collection Date** 24/02/2024 12:29PM 24/02/2024 1:06PM Age/Gender 36 Yrs/Male **Receiving Date** Report Date **IP/OP Location** O-OPD 24/02/2024 5:06PM Dr. EHS CONSULTANT

Referred By Report Status Final

Mobile No. 7976570610

HEMATOLOGY

| Test Name | Result | Unit | Biological Ref. Range |
|------------------------------|--------|----------------|--------------------------|
| CBC (COMPLETE BLOOD COUNT) | | | Sample: WHOLE BLOOD EDTA |
| HAEMOGLOBIN | 14.5 | g/dl | 13.0 - 17.0 |
| PACKED CELL VOLUME(PCV) | 43.0 | % | 40.0 - 50.0 |
| MCV | 88.7 | fl | 82 - 92 |
| MCH | 29.9 | pg | 27 - 32 |
| MCHC | 33.7 | g/dl | 32 - 36 |
| RBC COUNT | 4.85 | millions/cu.mm | 4.50 - 5.50 |
| TLC (TOTAL WBC COUNT) | 6.44 | 10^3/ uL | 4 - 10 |
| DIFFERENTIAL LEUCOCYTE COUNT | | | |
| NEUTROPHILS | 58.0 | % | 40 - 80 |
| LYMPHOCYTE | 33.1 | % | 20 - 40 |
| EOSINOPHILS | 1.1 | % | 1 - 6 |
| MONOCYTES | 7.3 | % | 2 - 10 |
| BASOPHIL | 0.5 L | % | 1 - 2 |
| PLATELET COUNT | 3.13 | lakh/cumm | 1.500 - 4.500 |

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method: - Calculation bysysmex. MCH: - Method: - Calculation bysysmex.
MCHC: - Method: - Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS : - Method: Optical detectorblock based on FlowcytometryEOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

0 - 15

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 20 H mm/1st hr

RESULT ENTERED BY: Mr. JITENDRA MARWAL

Dr. ABHINAY VERMA

Patient Name Lab No Mr. VIKAS KUMAR KABRA 4025009 UHID 40010835 **Collection Date** 24/02/2024 12:29PM 24/02/2024 1:06PM Age/Gender **Receiving Date** 36 Yrs/Male **Report Date** O-OPD **IP/OP Location** 24/02/2024 5:06PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 7976570610

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Page: 10 Of 11

Mr. VIKAS KUMAR KABRA **Patient Name** Lab No 4025009 UHID 40010835 **Collection Date** 24/02/2024 12:29PM 24/02/2024 1:06PM Age/Gender **Receiving Date** 36 Yrs/Male **Report Date IP/OP Location** O-OPD 24/02/2024 5:06PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 7976570610

X Ray

Test Name Result Unit Biological Ref. Range

X-RAY CHEST P. A. VIEW

Both lung fields are clear.

Both CP angles are clear.

Both hemi-diaphragms are normal in shape andoutlines.

Cardiac shadow is within normal limits.

Visualized bony thorax is unremarkable.

Correlate clinically& with other related investigations.

End Of Report

RESULT ENTERED BY : Mr. JITENDRA MARWAL

Dr. MRINAL CHOUDHARY MBBS,MD Radiodiagnosis

(Whoullary

RADIOLOGIST

DEPARTMENT OF RADIO DIAGNOSIS

| UHID / IP NO | 40010835 (5264) | RISNo./Status: | 4025009/ |
|---------------|--|----------------|--|
| Patient Name: | Mr. VIKAS KUMAR KABRA | Age/Gender: | 36 Y/M |
| Referred By: | Dr. EHS CONSULTANT | Ward/Bed No: | OPD |
| Bill Date/No: | 24/02/2024 11:41AM/ OPSCR23- 24/13929 | Scan Date : | |
| Report Date : | 24/02/2024 1:35PM | Company Name: | Mediwheel - Arcofemi Health Care Ltd. |

USG REPORT - ABDOMEN AND PELVIS

LIVER:

Is normal in size and shows diffuse increased echo texture.

No obvious focal lesion seen. No intra hepatic biliary radical dilatation seen.

GALL BLADDER:

Adequately distended with no obvious wall thickening/pericholecystic fat stranding/fluid. No obvious calculus/polyp/mass seen within.

PANCREAS:

Appears normal in size and shows uniform echo texture. The pancreatic duct is normal. No calcifications are seen.

SPLEEN:

Appears normal in size and it shows uniform echo texture.

RIGHT KIDNEY:

The shape, size and contour of the right kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

LEFT KIDNEY:

The shape, size and contour of the left kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

URINARY BLADDER:

Is normal in contour. No intraluminal echoes are seen. No calculus or diverticulum is seen.

PROSTATE:

Is normal in size, measuring approx. 22-23cc in volume.

No focal fluid collections seen.

IMPRESSION:

Grade-I fatty liver.

DR. RENU JADIYA

Rome Jadiya

Consultant - Radiology

MBBS, DNB

DEPARTMENT OF CARDIOLOGY

| UHID / IP NO | 40010835 (5264) | RISNo./Status: | 4025009/ |
|---------------|--|----------------------|----------|
| Patient Name: | Mr. VIKAS KUMAR KABRA | Age/Gender: | 36 Y/M |
| Referred By: | Dr. EHS CONSULTANT | Ward/Bed No: | OPD |
| Bill Date/No: | 24/02/2024 11:41AM/ OPSCR23- 24/13929 | Scan Date : | |
| Report Date: | 24/02/2024 1:09PM | Company Name: | Final |

REFERRAL REASON: HEALTH CHECKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

| Normal Normal | | | | | | | | |
|---------------|----------------|--------|--------|----------|-------------|----------------|----------|---------------|
| IVSD | 11.6 | 6-12mm | | | LVIDS | 29.9 | 20-40mm | |
| LVIDD | 48.2 | | 32- | 57mm | | LVPWS | 18.8 | mm |
| LVPWD | 10.1 | | 6-1 | 2mm | | AO | 34.7 | 19-37mm |
| IVSS | 18.8 | | J | mm | | LA | 37.1 | 19-40mm |
| LVEF | 62-64 | | > | 55% | | RA | - | mm |
| | <u>DOPPLEI</u> | R MEA | SUREN | 1ENTS & | & CALC | ULATIONS | <u>:</u> | |
| STRUCTURE | MORPHOLOGY | | VELOC | CITY (m/ | 's) | GRADIENT | | REGURGITATION |
| | | | | | | (mmHg <u>)</u> | | |
| MITRAL | NORMAL | E | 0.78 | e' | - | - | | NIL |
| VALVE | | A | 0.43 | E/e' | - | | | |
| TRICUSPID | NORMAL | | E 0.56 | | - | | NIL | |
| VALVE | | | A | 0 | 12 | | | |
| | | A 0.42 | | | | | | |
| AORTIC | NORMAL | 1.06 | | | - | | NIL | |
| VALVE | | | | | | | | |
| PULMONARY | NORMAL | 0.53 | | | | | NIL | |
| VALVE | | | | | | - | | |

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

Patient NameMr. VIKAS KUMAR BABRALab No634974

 UHID
 341147
 Collection Date
 24/02/2024
 2:57PM

 Age/Gender
 36 Yrs/Male
 Receiving Date
 24/02/2024
 3:04PM

 IP/OP Location
 O-OPD
 Report Date
 24/02/2024
 4:00PM

Referred By Dr. EHCC Consultant Report Status Final

Tilla



BIOCHEMISTRY

| Test Name | Result | Unit | Biological Ref. Range |
|-----------|--------|------|---|
| | | | Sample: WHOLE BLOOD EDTA |
| HBA1C | 5.4 | % | < 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes |
| | | | Known Diabetic Patients < 7 % Excellent Control 7 - 8 % Good Control > 8 % Poor Control |

Method: - Tetradecyltrimethylammonium bromide
Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient.
The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

End Of Report

 ${\bf RESULT\;ENTERED\;BY:Dr.\;SURENDRA\;SINGH}$

Dr. SURENDRA SINGH CONSULTANT & HOD MBBS MD PATHOLOGY

Mobile No.

9773349797

Dr. ASHISH SHARMA
CONSULTANT & INCHARGE PATHOLOGY
MBBS|MD| PATHOLOGY

Page: 1 Of 1